Mundipharma commences COPD trial
Mundipharma Research Limited (Mundipharma) has announced a major milestone in the development programme of flutiform® (fluticasone propionate/formoterol fumarate) for the treatment of Chronic Obstructive Pulmonary Disease (COPD) with the commencement of a key clinical trial.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: Industry News Respiratory Source Type: news
More News: Chronic Obstructive Pulmonary | Clinical Trials | Drugs & Pharmacology | Flonase | Flovent | Respiratory Medicine